These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33625688)

  • 1. Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches.
    Hybar H; Saki N; Maleknia M; Moghaddasi M; Bordbar A; Naghavi M
    Mol Biol Rep; 2021 Mar; 48(3):2703-2711. PubMed ID: 33625688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease.
    Waldram JD; Simon RA
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):693-703. PubMed ID: 27712764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
    Stevens WW; Schleimer RP
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):669-680. PubMed ID: 27712762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DRB and HLA-DQ genetic variability in patients with aspirin-exacerbated respiratory disease.
    Esmaeilzadeh H; Nabavi M; Amirzargar AA; Aryan Z; Arshi S; Bemanian MH; Fallahpour M; Mortazavi N; Rezaei N
    Am J Rhinol Allergy; 2015; 29(3):e63-9. PubMed ID: 25975240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.
    Dahlin A; Weiss ST
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):765-789. PubMed ID: 27712769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
    Cahill KN; Bensko JC; Boyce JA; Laidlaw TM
    J Allergy Clin Immunol; 2015 Jan; 135(1):245-52. PubMed ID: 25218285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the management of aspirin-exacerbated respiratory disease.
    Lee JH; Jung CG; Park HS
    Expert Rev Respir Med; 2018 Feb; 12(2):137-143. PubMed ID: 29249187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the Art: Medical treatment of aspirin exacerbated respiratory disease (AERD).
    Ta V; Simon R
    Am J Rhinol Allergy; 2015; 29(1):41-3. PubMed ID: 25590318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
    Ledford DK; Wenzel SE; Lockey RF
    J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin-exacerbated respiratory disease: clinical disease and diagnosis.
    Bochenek G; Niżankowska-Mogilnicka E
    Immunol Allergy Clin North Am; 2013 May; 33(2):147-61. PubMed ID: 23639705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
    Berges-Gimeno MP; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2002 Nov; 89(5):474-8. PubMed ID: 12452205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboxane A2 receptor +795T>C and chemoattractant receptor-homologous molecule expressed on Th2 cells -466T>C gene polymorphisms in patients with aspirin-exacerbated respiratory disease.
    Kohyama K; Hashimoto M; Abe S; Kodaira K; Yukawa T; Hozawa S; Morioka J; Inamura H; Yano M; Ota M; Sagara H; Kurosawa M
    Mol Med Rep; 2012 Feb; 5(2):477-82. PubMed ID: 22101342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease.
    Kim TH; Lee JY; Park JS; Park SW; Jang AS; Lee JY; Byun JY; Uh ST; Koh ES; Chung IY; Park CS
    PLoS One; 2011; 6(8):e22711. PubMed ID: 21829647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
    Steinke JW; Payne SC; Borish L
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):719-734. PubMed ID: 27712766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
    White AA; Stevenson DD; Simon RA
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease.
    Trinh HKT; Pham DL; Choi Y; Kim HM; Kim SH; Park HS
    Clin Exp Allergy; 2018 Nov; 48(11):1464-1473. PubMed ID: 30126026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible association between ZNRD1 and aspirin-induced airway bronchoconstriction in a Korean population.
    Pasaje CF; Bae JS; Park BL; Cheong HS; Jang AS; Uh ST; Kim MK; Kim JH; Park TJ; Lee JS; Kim Y; Park CS; Shin HD
    J Investig Allergol Clin Immunol; 2012; 22(3):193-200. PubMed ID: 22697009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid Mediators in Aspirin-Exacerbated Respiratory Disease.
    Parker AR; Ayars AG; Altman MC; Henderson WR
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):749-763. PubMed ID: 27712768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors driving the aspirin exacerbated respiratory disease phenotype.
    Steinke JW; Borish L
    Am J Rhinol Allergy; 2015; 29(1):35-40. PubMed ID: 25590316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical updates in aspirin-exacerbated respiratory disease.
    Laidlaw TM
    Allergy Asthma Proc; 2019 Jan; 40(1):4-6. PubMed ID: 30582489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.